Antidepressant Therapy (Imipramine and Citalopram) for Irritable Bowel Syndrome: A Double-Blind,Randomized, Placebo-Controlled Trial |
| |
Authors: | Nicholas J Talley John E Kellow Philip Boyce Christopher Tennant Sandy Huskic Michael Jones |
| |
Institution: | (1) Department of Medicine, Nepean Hospital, University of Sydney, Sydney, NSW, Australia;(2) Clinical Enteric Neuroscience Translational and Epidemiological Research Program, Mayo Clinic College of Medicine, 200 First Street S.W., PL-6-56, Rochester, MN 55905, USA;(3) Department of Psychological Medicine, Royal North Shore Hospital, Sydney, NSW, Australia;(4) Department of Medicine, Royal North Shore Hospital, University of Sydney, Sydney, Australia;(5) Department of Psychological Medicine, Westmead Hospital, Sydney, NSW, Australia;(6) Psychology Department, Macquarie University, North Ryde, NSW, Australia |
| |
Abstract: | Background The efficacy of antidepressants in irritable bowel syndrome (IBS) is controversial. No trials have directly compared a tricyclic
with a selective serotonin reuptake inhibitor. Our aim was to determine whether imipramine and citalopram are efficacious
in IBS.
Methods This was a randomized, double-blind, placebo-controlled, parallel group pilot trial with imipramine (50 mg) and citalopram
(40 mg).
Results Of 51 IBS patients randomized, baseline characteristics were comparable among the treatment arms; the majority was diarrhea-predominant.
Adequate relief of IBS symptoms (primary endpoint) was similar for each treatment arm. Improvements in bowel symptom severity
rating for interference (P = 0.05) and distress (P = 0.02) were greater with imipramine versus placebo, but improvements in abdominal pain were not. There was a greater improvement
in depression score (P = 0.08) and in the SF-36 Mental Component Score (P = 0.07), with imipramine. Citalopram was not superior to placebo. Approximately 20% of the variance in scores was explained
by treatment differences for abdominal pain, bowel symptom severity disability, depression and the mental component of the
SF-36.
Conclusion Neither imipramine nor citalopram significantly improved global IBS endpoints over placebo. |
| |
Keywords: | Antidepressant Irritable bowel syndrome Randomized trial |
本文献已被 PubMed SpringerLink 等数据库收录! |
|